case_images: PMC10693278_01
case_images: Absolute neutrophil count of the patient since the diagnosis of Grave's disease and initiation of antithyroid drugs.
case_images: IMCRJ-16-783-g0001.jpg
case_images: PMC10693278_01_IMCRJ-16-783-g0001.jpg
case_images: f0001
case_images: She had gained some weight and had a reduction in her absolute neutrophil count (Figure 1), hinting toward compliance with the medications. 
case_images: Trend of TFTs of the patient from the time of diagnosis till pre-thyroidectomy follow-up. (A) Shows the trend of T3 level, (B) Shows the trend of T4 level of the patient since diagnosis with respective treatments.
case_images: IMCRJ-16-783-g0002.jpg
case_images: PMC10693278_01_IMCRJ-16-783-g0002.jpg
case_images: f0002
case_images: TD due to persistently deranged TFTs (TSH: <0.01, T3: 12, T4: 40.4). Patient had a partial response to the increased dose of PTU with repeat TFTs after one month showing TSH <0.01, T3: 7, T4: 25.5. The TFT trend of the patient from diagnosis to the last follow-up is graphed (Figure 2). Figure 2A shows the trend of T3 level, Figure 2B shows the trend of T4 level through the patient timeline. 
case_images: Mechanism of thyroid hormone production with mechanism of action of antithyroid drugs. Red Crosses denote the potential causes of resistance (inadequate uptake of drug, inability of action of the drug despite adequate uptake). Figure concept taken from Katzung and Trevor's Pharmacology Examination and Board Review.
case_images: IMCRJ-16-783-g0003.jpg
case_images: PMC10693278_01_IMCRJ-16-783-g0003.jpg
case_images: f0003
case_images: Figure 2A shows the trend of T3 level, Figure 2B shows the trend of T4 level through the patient timeline. 